Angina

Clinical Trial Finder

Many patients with angina are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic Angina

Condition:   Quality of Life
Interventions:   Drug: Caduet 10Mg-20Mg Tablet;   Drug: NorvasC® 10 mg Tablets
Sponsor:   Kosin University Gospel Hospital
Not yet recruiting - verified February 2017

The Impact of Depression and/or Anxiety on PCI Patients

Conditions:   Acute Coronary Syndrome;   MAjor Depressive Disorder;   Generalized Anxiety Disorder
Intervention:   Other: antidepressive and anti-anxiety therapy
Sponsors:   First Affiliated Hospital Xi'an Jiaotong University;   Shaanxi Provincial People's Hospital;   Xi'an Central Hospital;   Baoji Central Hospital;   Baoji People's Hospital;   General Hospital of Ningxia Medical University;   The People's Hospital of Ningxia;   Wuzhong People's Hospital;   The First Hospital of Lanzhou University;   LanZhou University;   First Affiliated Hospital of Xinjiang Medical University;   the People's Hospital of Xinjiang Uygur Autonomous Region;   The First People's Hospital of Kashgar Erea;   the First Division Hospital of Xinjiang Production and Construction Corps
Not yet recruiting - verified December 2016

Implication of Cardiac Shock Wave Therapy on Coronary Heart Disease

Condition:   Cardiac Ischemia
Interventions:   Device: Cardiac shock wave therapy;   Other: Sham cardiac shock wave (Control group)
Sponsor:   Beijing Hospital
Recruiting - verified February 2017

Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris

Conditions:   Refractory Angina Pectoris;   Gene Transfer;   Coronary Artery Disease
Interventions:   Drug: AdvVEGF-D;   Drug: Control Rx
Sponsors:   Kuopio University Hospital;   Queen Mary University of London;   University College, London;   Medizinische Universitaet Wien;   Servicio Madrileño de Salud, Madrid, Spain;   FinVector Vision Therapies Oy;   Śląski Uniwersytet Medyczny w Katowicach;   Rigshospitalet, Denmark;   Euram Limited
Not yet recruiting - verified January 2017

Comparing TR Band to Statseal in Conjunction With TR Band

Conditions:   Arterial Occlusion;   Angina Pectoris;   Cardiovascular Diseases;   Atherosclerosis;   Hematoma;   Anticoagulant-Induced Bleeding;   Coronary Artery Disease
Interventions:   Device: StatSeal;   Device: TR Band
Sponsor:   VA Long Beach Healthcare System
Not yet recruiting - verified February 2017

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Recruiting - verified February 2017

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Conditions:   Cardiomyopathy, Hypertrophic;   Cardiomyopathy, Hypertrophic, Familial
Intervention:   Drug: Perhexiline
Sponsor:   Heart Metabolics Limited
Recruiting - verified February 2017

Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Bassett Healthcare;   Baylor University
Recruiting - verified February 2017

Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure

Conditions:   Essential Hypertension;   Chronic Stable Angina;   Congestive Heart Failure
Intervention:  
Sponsor:   Chong Kun Dang Pharmaceutical
Enrolling by invitation - verified February 2017

COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials

Conditions:   Stable Angina;   Unstable Angina;   STEMI;   NSTEMI;   Coronary Disease
Interventions:   Device: COMBO-Stent;   Drug: Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran;   Device: Any drug eluting stent oder bare metal sent;   Drug: ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
Sponsors:   IHF GmbH - Institut für Herzinfarktforschung;   OrbusNeich
Withdrawn - verified February 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified February 2017

Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule

Conditions:   Peripheral Arterial Disease;   Intermittent Claudication
Interventions:   Drug: Danshen Gegen Capsule;   Drug: Placebo
Sponsor:   Chinese University of Hong Kong
Recruiting - verified February 2017

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2017

DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease

Condition:   Coronary Atherosclerosis
Intervention:  
Sponsors:   University of Surrey;   Ashford and St. Peter's NHS Trust
Completed - verified February 2017

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Completed - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Completed - verified February 2017

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention &Amp; Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute;   Janssen Research & Development, LLC
Recruiting - verified February 2017

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified February 2017

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition:   Crohn's Disease
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Completed - verified February 2017

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Conditions:   Atherosclerosis;   Hypercholesterolemia
Interventions:   Drug: Statin Drugs;   Other: HMG-CoA Reductase Inhibitors
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed - verified March 21, 2016

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Darapladib 160 mg;   Drug: Placebo;   Other: Standard Therapy
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Completed - verified February 2017

Exercise-training Before Coronary Artery Bypass Graft (CABG)

Conditions:   Angina;   Coronary Artery Disease
Intervention:   Behavioral: Exercise training
Sponsor:   Norwegian University of Science and Technology
Completed - verified February 2017